News headlines about Pieris Pharmaceuticals (NASDAQ:PIRS) have been trending somewhat positive this week, according to Accern Sentiment. Accern identifies negative and positive media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Pieris Pharmaceuticals earned a coverage optimism score of 0.16 on Accern’s scale. Accern also gave headlines about the biotechnology company an impact score of 46.2326777192581 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

Here are some of the news headlines that may have effected Accern’s analysis:

A number of analysts recently weighed in on PIRS shares. Rodman & Renshaw started coverage on shares of Pieris Pharmaceuticals in a research note on Tuesday, May 30th. They issued a “buy” rating and a $9.00 target price on the stock. TheStreet raised shares of Pieris Pharmaceuticals from a “d” rating to a “c-” rating in a research note on Wednesday, May 3rd. Oppenheimer Holdings, Inc. set a $9.00 target price on shares of Pieris Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, April 12th. Finally, BidaskClub cut shares of Pieris Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, July 26th. Four research analysts have rated the stock with a buy rating, The stock presently has an average rating of “Buy” and a consensus price target of $8.00.

Pieris Pharmaceuticals (NASDAQ PIRS) opened at 5.29 on Tuesday. Pieris Pharmaceuticals has a 52-week low of $1.30 and a 52-week high of $6.20. The firm has a 50-day moving average of $5.21 and a 200-day moving average of $3.43. The firm’s market capitalization is $227.83 million.

Pieris Pharmaceuticals (NASDAQ:PIRS) last released its quarterly earnings results on Wednesday, May 10th. The biotechnology company reported ($0.19) EPS for the quarter, missing analysts’ consensus estimates of $0.16 by $0.35. Pieris Pharmaceuticals had a negative return on equity of 95.10% and a negative net margin of 449.33%. The business had revenue of $1.34 million for the quarter, compared to the consensus estimate of $32.30 million. On average, equities research analysts forecast that Pieris Pharmaceuticals will post ($0.69) EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This report was posted by Daily Political and is the property of of Daily Political. If you are reading this report on another publication, it was copied illegally and republished in violation of US and international trademark and copyright law. The original version of this report can be viewed at

Pieris Pharmaceuticals Company Profile

Pieris Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids.

Insider Buying and Selling by Quarter for Pieris Pharmaceuticals (NASDAQ:PIRS)

Receive News & Ratings for Pieris Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals Inc. and related companies with's FREE daily email newsletter.